Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT05216835 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Classical Hodgkin Lymphoma

Interventions

DRUG: Sabestomig (AZD7789)

Sponsor

AstraZeneca

Collaborators

[object Object]